Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects financial challenges with declining revenue and high cash burn, despite cost reduction efforts. The lack of revenue guidance and competitive market pressures add uncertainty. While collaborations and strategic shifts are positive, the financial health remains concerning. The market is likely to react negatively, given the ongoing losses and operational risks.
Key Financial Performance
Cash and Cash Equivalents $5.3 million as of June 30, 2024, down from $8.7 million as of December 31, 2023.
Stockholders' Equity $4.1 million as of June 30, 2024, down from $8.3 million as of December 31, 2023.
Net Loss per Share $0.68 per share for Q2 2024, improved from $0.98 per share for Q2 2023.
Revenue $279,000 for Q2 2024, down from $490,000 for Q2 2023.
General and Administrative Expenses $2.1 million for Q2 2024, down from $2.7 million for Q2 2023, primarily due to lower employee compensation and decreased investor relation costs.
Operations Expenses $893,000 for Q2 2024, down from $993,000 for Q2 2023, primarily due to decreased cloud computing expenses.
Sales and Marketing Expenses $284,000 for Q2 2024, down from $429,000 for Q2 2023, primarily due to lower employee compensation including sales commissions.
Net Cash Used in Operating Activities $6.6 million for the six months ended June 30, 2024, down from $7.0 million for the comparable period in 2023.
Net Loss $3.2 million for Q2 2024, improved from $3.9 million for Q2 2023.
Accumulated Deficit $175 million as of June 30, 2024, up from $168 million as of December 31, 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: Launched a novel organ-specific 3D cell culture technology that mimics human tissue architecture, enhancing drug candidate testing.
Market Expansion: Expanded AI and machine learning offerings for biomarker discovery in oncology, targeting a market valued at over $51 billion in 2024.
Collaboration: First collaboration with the University of Michigan for drug discovery, leveraging their extensive natural products library.
Operational Efficiency: Implemented a strategic cost reduction initiative expected to save approximately $2.5 million annually, consolidating operations from Birmingham to Pittsburgh.
Financial Position: Raised $5.0 million in capital to strengthen cash position and extend runway.
Strategic Shift: Focus on core capabilities in AI-driven drug discovery, reallocating resources to enhance operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that its actual performance may materially differ from forward-looking statements due to substantial risks, uncertainties, and assumptions about operations and investments.
Cost reduction initiative: The company implemented a strategic cost reduction initiative, consolidating operations from Birmingham to Pittsburgh, which may impact operational efficiency and employee morale.
Financial performance: The company reported a net loss of $3.2 million for Q2 2024, with an accumulated deficit of $175 million, indicating ongoing financial challenges.
Market competition: The biomarker discovery market is highly competitive, valued at over $51 billion in 2024, posing challenges in establishing a significant market presence.
Regulatory issues: The company operates in a heavily regulated industry, which may pose risks related to compliance and approval processes for new technologies and products.
Supply chain challenges: The company’s reliance on external partnerships and collaborations for drug discovery may expose it to supply chain risks and delays.
Cash burn rate: The company’s cash burn rate remains high, with $6.6 million used in operating activities for the first half of 2024, necessitating ongoing capital raises to maintain operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Biomarker Discovery Initiative: Expanded AI and machine learning offerings to discover novel biomarkers for predicting patient outcomes and drug responses in oncology.
3D Cell Culture Technology: Launched a novel organ-specific 3D cell culture technology to better mimic human tissue architecture, enhancing drug candidate testing.
ACE Initiative: Progress made with the Accelerating Compound Exploration program, resulting in collaboration with the University of Michigan for drug discovery.
Cost Reduction Initiative: Implemented a strategic cost reduction initiative expected to save approximately $2.5 million annually by consolidating operations.
Cash Burn Reduction: Expected reduction in cash burn by approximately 20% due to operational streamlining.
Revenue Expectations: No specific revenue guidance provided, but noted a decrease in revenue from $490,000 in Q2 2023 to $279,000 in Q2 2024.
Future Collaborations: Plans to validate capabilities through development collaborations with biopharmaceutical partners.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Capital Raise: The company raised $5.0 million in total over the last few months to bolster its cash balance sheet and extend its runway.
ATM Facility: In May, the company raised $3.7 million, net of $0.6 million of issuance costs, through its at-the-market facility by issuing 1.6 million shares.
Warrant Inducement Transaction: In July, the company raised an additional $1.3 million in gross proceeds through the exercise of 958,000 warrants.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:No specific questions were asked during the Q&A session.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACE
America
Biologics
Birmingham
Blacher Chief
Chairman Chief
Sales
University Michigan
biomarker discovery
biomarkers outcome
candidate
capability development
capability role
cash balance
core
cost
decrease employee
discovery biomarkers
discovery development
discovery initiative
drug tumor
end
facility
inducement transaction
issuance
loss
marketing
molecule
need
period decrease
proceeds
program
reduction
relevance
runway
sample biobank
saving
selection
share
POAI Transcript
Predictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks Transcript
Unknown11-17
The earnings call reveals minimal revenue, significant net loss, liquidity concerns, and operational risks in a competitive AI infrastructure market. Despite strategic initiatives, the company's financial health is precarious with a low cash position and high non-cash losses. The Q&A section did not provide clarity on management's responses, adding uncertainty. Overall, these factors suggest a negative market reaction.
Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript
Unknown8-14
The earnings call reflects financial challenges with declining revenue and high cash burn, despite cost reduction efforts. The lack of revenue guidance and competitive market pressures add uncertainty. While collaborations and strategic shifts are positive, the financial health remains concerning. The market is likely to react negatively, given the ongoing losses and operational risks.
Predictive Oncology Inc. (POAI) Q1 2024 Earnings Call Transcript
Unknown5-15
The earnings call indicates financial challenges, with increased net losses, declining cash reserves, and heightened operational expenses. Despite revenue growth, the company faces significant competition and regulatory hurdles. The Q&A session highlights promising collaborations and study results, but these do not offset the financial strain. Additionally, the lack of shareholder return discussions and the absence of a strategic plan exacerbate concerns. Overall, the negative financials and competitive pressures suggest a likely negative stock price movement over the next two weeks.
Predictive Oncology Inc. (POAI) Q3 2023 Earnings Call Transcript
Unknown11-14
The earnings call highlights several concerns: declining cash reserves, high operating expenses, and dependence on partnerships. Despite revenue growth and improved gross margin, the company faces profitability challenges. The Q&A reveals reliance on future collaborations, which are uncertain. The market is competitive, and regulatory risks persist. Without a new partnership announcement or optimistic guidance, and given the financial health issues, the stock is likely to react negatively.
POAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
